KORU Medical Systems Q2 2026 Results: 18% Revenue Rise and First Profit

KORU Medical Systems, Inc. posted a 18% quarter‑over‑quarter revenue increase and posted its first net profit since 2019, marking a pivotal shift in its growth trajectory.

Core Quarter Highlights

■12% domestic growth driven by outpacing the subcutaneous immunoglobulin (SCIG) market and strong patient retention.

■International revenue surged 59%, fueled by distributor‑led conversions to prefilled syringe (PFS) formats across Europe.

■The US FDA 510(k) submission for Phesgo was withdrawn for label‑specific reasons, steering the domestic oncology strategy toward high‑volume biologics.

■Acquisition of a connected monitoring technology asset aims to embed data‑driven insights into the mechanical platform, enhancing patient adherence and trial integrity.

International Expansion and Market Dynamics

■Full‑year revenue guidance narrowed to $47.5M‑$48.5M, reflecting a more measured ramp‑up in non‑tender international markets as distribution and reimbursement pathways mature.

■The European PFS transition positions the Freedom system to capture incremental growth in the emerging secondary immunodeficiency (SID) market.

■Meaningful revenue contributions from new geographies are expected to shift into 2027, with a more moderate growth pace in H2 2026.

Financial Outlook and Margin Expansion

■Gross margin guidance lifted to 62%‑64% after a multi‑year supplier contract extension secured better pricing and de‑risked the lower end of prior estimates.

■Positive adjusted EBITDA is projected for the full year 2026, with continued investments in R&D and sales & marketing.

■Cash guidance adjusted to a year‑end balance greater than $7.5M to accommodate the technology acquisition and associated R&D headcount costs.

Operational Risks and Structural Updates

■Pharma Services revenue fell 35% due to customer order timing, highlighting the inherent quarterly variability of clinical‑trial‑related business.

■Biogen's acquisition of Apellis may create near‑term timing challenges for clinical trial activity during standard post‑acquisition integration.

■The shift to focus on international markets for Phesgo reduced the estimated annual infusion opportunity to 600,000 units, though international oncology efforts remain active.

KORU Medical Systems' Q2 performance demonstrates balanced progress on both domestic and international fronts. The European PFS shift and a high‑margin supplier agreement serve as critical catalysts for profitability. Nonetheless, volatility in Pharma Services and integration risks from large‑scale acquisitions could introduce short‑term turbulence. Investors should closely monitor the 2027 timeline for new geography revenue contributions and upcoming product launch schedules.